Andrea B. Posted June 17, 2003 Share Posted June 17, 2003 Review of cancer drug to get fast track at FDA Cell Therapeutics Inc. said yesterday that its lung-cancer treatment will get a faster review from the Food and Drug Administration because it addresses an unmet medical need. The company's Xyotax medicine for advanced, non-small-cell lung cancer is in the final stage of two clinical trials, and Cell Therapeutics may file for the drug's approval by the end of 2004, it said in a statement. This type of lung cancer is incurable and current treatments have only a modest benefit, the company said. Fast-track designation means the agency will speed review of an application for a treatment of a life-threatening condition that has demonstrated the potential to address an unmet need. Xyotax contains paclitaxel, the main ingredient in Bristol-Myers Squibb Co.'s Taxol cancer treatment. http://seattlepi.nwsource.com/business/ ... brf17.html Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.